BICO

INTERIM REPORT Q2 2026

EARNINGS CALL
–
WEDNESDAY, AUGUST 19, 2026

DISCLAIMER

You must read the following before continuing. The following applies to this document and the information provided in this presentation by BICO AB (publ) (the "Company") or any person on behalf of the Company and any other material distributed or statements made in connection with such presentation (the "Information"), and you are therefore advised to carefully read the statements below before reading, accessing or making any other use of the Information. In accessing the Information, you agree to be bound by the following terms and conditions.

The Information does not constitute or form part of, and should not be construed as, an offer of invitation to subscribe for, underwrite or otherwise acquire, any securities of the Company or a successor entity or any existing or future subsidiary or affiliate of the Company, nor should it or any part of it form the basis of, or be relied on in connection with, any contract to purchase or subscribe for any securities of the Company or any of such subsidiaries or affiliates nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever. Specifically, this presentation does not constitute a "prospectus" within the meaning of the U.S. Securities Act of 1933, as amended.

The Information may not be reproduced, redistributed, published or passed on to any other person, directly or indirectly, in whole or in part, for any purpose. The Information is not directed to, or intended for distribution to or use by, any person or entity that is a citizen or resident of, or located in, any locality, state, country or other jurisdiction where such distribution or use would be contrary to law or regulation or which would require any registration or licensing within such jurisdiction. The Information is not for publication, release or distribution in the United States, the United Kingdom, Australia, Canada or Japan, or any other jurisdiction in which the distribution or release would be unlawful.

All of the Information herein has been prepared by the Company solely for use in this presentation. The Information contained in this presentation has not been independently verified. No representation, warranty or undertaking, expressed or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the Information or the opinions contained herein. The Information contained in this presentation should be considered in the context of the circumstances prevailing at that time and has not been, and will not be, updated to reflect material developments which may occur after the date of the presentation. The Company may alter, modify or otherwise change in any manner the content of this presentation, without obligation to notify any person of such revision or changes.

This presentation may contain certain forward-looking statements and forecasts which relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on the Company's operations, financial position and earnings. The terms "anticipates", "assumes","believes", "can", "could", "estimates", "expects", "forecasts", "intends", "may", "might", "plans", "should", "projects", "will", "would" or, in each case, their negative, or other variations or comparable terminology are used to identify forward-looking statements. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied in a forward-looking statement or affect the extent to which a particular projection is realised. Factors that could cause these differences include, but are not limitedto, implementation of the Company's strategy and its ability to further grow, risks associated with the development and of the Company's products, ongoing research and development, the ability to commercialize the Company's products, technology changes and new products in the Company's potential market and industry, the ability to develop new products, the impact of competition, changes in general economy and industry conditions and legislative, regulatory and political factors. While the Company always intends to express its best judgment when making statements about what it believes will occur in the future, and although the Company bases these statements on assumptions that it believe to be reasonable when made, these forward-looking statements are not a guarantee of its performance, and you should not place undue reliance on such statements. Forward-looking statements are subjectto many risks, uncertainties and other variable circumstances. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the Company's control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this presentation are made only as of the date hereof. The Company does not undertake, and specifically decline, any obligation to update any suchstatements or to publicly announce the results of any revisions to any of such statements to reflect future events or developments.

Anders Fogelberg, President and CEO of BICO Group from September 1, 2026

- 25+ years of global industry experience from management positions such as a Managing Director for the SKF Group in Malaysia and Indonesia
- CEO for med tech company Bellman & Symfon and Chief Marketing Officer and Head of Sales for life science start-up Profundus
- Joined BICO Group in 2024 as Chief Commercial Officer

Earnings Call Agenda

Maria Forss
President & CEO

Ewa Linsäter
CFO

- **Summary Q2 2026**
- **Group Financial Performance**
- **Continuous Product Innovation**
- **Concluding Remarks**
- **Q&A**

Q2 2026 I Improved Profitability and AI Advancements

336
NET SALES
SEKm

7
ORGANIC SALES
GROWTH
%

20
ADJUSTED
EBITDA
SEKm

-53
OPERATING CASH
FLOW
SEKm



BICO's Portfolio Supports with Workflows Along Drug and Diagnostic Development to Automate Labs

BICO's current strengths and technologies are largely grouped into three fields

Molecular biology

- **Single-cell Proteomics**: CELLENION BY BICO, SCIENION BY BICO
- **Next Generation Sequencing (NGS)**: DISPENDIX BY BICO, QINSTRUMENTS BY BICO

Drug Discovery

- **Assay Development**
- **High-throughput Screening (HTS)**

DISPENDIX BY BICO, CYTENA BY BICO, QINSTRUMENTS BY BICO

Bioprocessing

- **Cell Line Development (CLD)**: CYTENA BY BICO, QINSTRUMENTS BY BICO

Across all three fields

- **Integrated Systems & Automation**: BIOSERO BY BICO
- **Microscopic Imaging**: ECHO BY BICO

Drug Discovery

- **Bioprinting**: ADVANCED BIOMATRIX BY BICO, CELLINK BY BICO

Sources: Company information

The Global Challenge

Long and costly clinical stages combined with low success rate comprise a global challenge for the drug development industry



> USD 2bn
Development costs

~ 10%
Probability of approval after successful phase 1

> 10 years
Discovery to approval

BICO Lab Automation Provides the Execution & Validation layer

converting AI hypotheses into proven experimental evidence

01

AI Hypothesis Generation

Generative models and predictive biology produce candidates at exponential speed.

↑ *Throughput demand*

02 THE CRITICAL LAYER

AI-Powered Wet Lab Automation

- High-throughput automation
- Trusted, reproducible data
- Human-in-the-loop oversight

03

Validated Evidence

Reproducible, compliant, scale-ready results that de-risk every downstream decision.

↓ *Time-to-decision*

- More AI-driven candidates mean **more experiments, not fewer**
- **AI acceleration shifts the bottleneck to the wet lab**
- The wet lab becomes even more mission-critical; **the indispensable infrastructure that makes AI-powered biotech work**

BICO Leads the way in Solving the Challenges in Life Science with Speed, Accuracy, and Efficiency

Speed	• Reducing the time to find optimal candidates for treatment therapies • Driving forward a personalized approach in treatment
Accuracy	• Enabling the development of physiologically relevant models • Enhancing reproducibility through automated processes that reduce variability in experimental outcomes
Efficiency	• Maximize productivity of automated laboratory equipment and scientists

Summary Q2 2026

Summary I Q2 2026

NET SALES	ADJUSTED EBITDA	CASH FLOW FROM OPERATING ACTIVITIES
SEK 336m	**SEK 20m**	**SEK -53m**

ORGANIC SALES GROWTH	ADJUSTED EBITDA MARGIN	NWC/LTM SALES
7%	**6%**	**10%**

All numbers in this presentation refer to continuing operations unless otherwise stated.
MatTek and Visikol have been classified as discontinued operations with retroactive effect.

Group Financial Performance

Sales Development (SEKm)



- Gradual market recovery
- Sales SEK 336m, an organic growth of 7%
- Strong bench top instrument and consumables sales
- Growth YoY in Europe and Asia
- Longer lead times for larger automation investments
- Improved gross profit of 14 percentage points

Adjusted EBITDA (SEKm) and Margin (%)



- Adjusted EBITDA SEK 20m
- Adjusted EBITDA margin 6%
- Improvement of adjusted EBITDA margin of 21 percentage points
- Commercial and operational excellence activities drives improved profitability
- Restructuring project launched in Q1 progresses according to plan

Cash Flow and Financial Position

- **Cash flow from operating activities, SEK -53m**
  - includes impact from changes in working capital of SEK -54m
- **Cash reserves by end of the quarter SEK 628m**

Development in Net Working Capital between Q2 2025 and Q2 2026*



* All numbers on this slide excludes MatTek and Visikol figures

Continuous Product Innovation

R&D Pipeline & Roadmap



AI-Powered Confluency on Rebel & Revolve

ECHO's new Confluency AI turns one of cell culture's most subjective steps into a quantitative reproducible metric — delivered as a licensed software feature to Rebel and Revolve systems already in the field.

±15 pts variation

between two scientists eyeballing the same flask — 60% vs 75%.

1 click

Instant measurement at image capture, enabled by AI-powered cell analysis.

BEFORE ANALYSIS

AFTER ANALYSIS — AI OVERLAY

WHY IT MATTERS

PERFORMANCE
Objective, quantitative confluency

WORKFLOW
A number the moment you image

MONETIZATION
Software attached on installed hardware

Tipless DNA Cleanup on the G.PURE GEN 2

G.PURE GEN 2 replaces tip-based magnetic bead cleanup with centrifugal liquid evacuation — removing the consumable from the workflow entirely and collapsing a 20-minute plate cleanup into 2 minutes.

576 → 0 tips

per 96-well plate — about 300,000 a year for a mid-sized laboratory.

10x faster

Time to purify 96 samples is reduced from 20 min to 2 min, significantly increasing throughput.

WHERE THE SAVINGS COME FROM

CONSUMABLE WASTE

The 576-tip plate becomes a zero-tip plate

SPEED

Whole plates in 2 to 10 minutes

DATA QUALITY

Fewer failed libraries downstream

Thank you!

Maria Forss, President and CEO until August 31, 2026, and transition into a senior advisory role to support seamless handover until November 30, 2026.

Q&A

Financial Calendar

NOVEMBER 11, 2026
Q3 Report 2026

FEBRUARY 17, 2027
Year-end report 2026

Contact

MARIA FORSS, CEO AND PRESIDENT
BICO GROUP AB
Phone: EA Elisabeth Lindell, +46 761 73 40 59
E-mail: mf@bico.com

EWA LINSÄTER, CFO
BICO GROUP AB
Phone: +46 766 33 32 33
E-mail: ewa.linsater@bico.com

BICO leverages a global portfolio of pioneering brands fusing automation, intelligence, and data to unlock scientific discovery at scale in pharma and biotech.

With 53,600+ instruments installed in over 65 countries, BICO products, software, and solutions are found in more than 3,500 laboratories, including the world's top 20 pharmaceutical companies, and have been cited in over 13,000 publications. BICO strives towards the vision to enable life-science labs to accelerate the discoveries that change lives.


BICO